• PolyMedix Inc., of Radnor, Pa., added Stephen T. Sonis to its scientific advisory board.

• Progenitor Cell Therapy, of New York, named Timothy Fong vice president of technology and product development and appointed David O'Neill director of R&D.

• Prosonix, of Oxford, UK, added Ken Cunningham to its board and named Peter Barnes, Marianne Mann and John Pritchard to its new scientific advisory board chaired by Ken Cunningham.

• ProtAffin AG, of Graz, Austria, appointed Mike Bartley chief development officer.

• Proteostasis Therapeutics, of Cambridge, Mass., appointed Mark J. Enyedy CEO.

• Protox Therapeutics Inc., of San Diego, appointed Alexander Casdin chief financial officer.

• Reata Pharmaceuticals Inc., of Irving, Texas, added several new management positions: Paul Audhya as vice president of development and chief medical officer; Hilary Malone as vice president and chief regulatory and compliance officer; Sean Nolan as vice president and chief commercial officer; and Jim Rouse as vice president and chief information officer. The firm also added Nancy Wysenski to its board.

• Redwood Bioscience, of Emeryville, Calif., appointed Peter Van Vlasselaer executive chairman.

• S1 Pharmaceuticals Inc., of Jersey City., N.J., appointed Robert Taylor Segraves and Robert Pyke to its scientific advisory board.

• Soligenix Inc., of Princeton, N.J., named Jeffrey Hyams, James Markowitz and Joel Rosh to its medical advisory board.

• Spectrum Pharmaceuticals Inc., of Henderson, Nev., appointed Brian Holzer executive director of brand management.

• Sucampo Pharmaceuticals Inc., of Bethesda, Md., appointed Cary J. Claiborne chief financial officer.

• Synthetic Genomics Vaccines Inc., of La Jolla, Calif., appointed Sammy J. Farah president.

• Tengion Inc., of East Norriton, Pa., appointed Scott Flora to its board.

• Threshold Pharmaceuticals Inc., of South San Francisco, appointed Nipun Davar vice president of pharmaceutical development and manufacturing.

• Tranzyme Pharma Inc., of Research Triangle Park, N.C., appointed Franck Rousseau chief medical officer.

• Trimel Pharmaceuticals Corp., of Toronto, appointed John Friedrichsen to its board.

• Vanda Pharmaceuticals Inc., of Rockville, Md., named Bob Repella senior vice president and chief commercial officer.

• Vermillion Inc., of Austin, Texas, named Donald Munroe chief scientific officer and vice president of R&D.

• YM BioSciences Inc., of Mississauga, Ontario, proposed Catherine Mackey for nomination to its board.

• Zafgen Inc., of Cambridge, Mass., named Frances K. Heller to its board.